Colorectal cancer: The diagnosis and management of colorectal cancer
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg131
Recommendations on surgery and colonic stents in acute large bowel obstruction and on stage I rectal cancer in sections 1.2.2 and 1.2.4 have been added. The addendum to NICE guideline CG131 contains details of the methods and evidence used to update these recommendations.
Colorectal cancer is one of the most common cancers in the UK after breast and lung cancer, with approximately 40,000 new cases registered each year. Occurrence of colorectal cancer is strongly related to age, with almost three‑quarters of cases occurring in people aged 65 or over. Colorectal cancer is the second most common cause of cancer death in the UK.
Around half of people diagnosed with colorectal cancer survive for at least 5 years after diagnosis.
The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.
This guideline recommends some medicines for indications for which they do not have a UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. The patient (or those with authority to give consent on their behalf) should provide informed consent, which should be documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices for further information. Where recommendations have been made for the use of medicines outside their licensed indications ('off‑label use'), these medicines are marked with a footnote in the recommendations.